tbuckley/cabot-search huggingface dataset:
Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors
Authors: Rocio Garcia-Carbonero, Miriam Bazan-Peregrino, Marta Gil-Martín, Rafael Álvarez, Teresa Macarulla, Maria C Riesco-Martinez, Helena Verdaguer, Carmen Guillén-Ponce, Martí Farrera-Sal, Rafael Moreno, Ana Mato-Berciano, Maria Victoria Maliandi, Silvia Torres-Manjon, Marcel Costa, Natalia del Pozo, Jaime Martínez de Villarreal, Francisco X Real, Noemí Vidal, Gabriel Capella, Ramon Alemany, Emma Blasi, Carmen Blasco, Manel Cascalló, Ramon Salazar
Journal: Journal for ImmunoTherapy of Cancer (2022)

VCN-01 is an oncolytic adenovirus (Ad5 based) designed to replicate in cancer cells with dysfunctional RB1 pathway, express hyaluronidase to enhance virus intratumoral spread and facilitate chemotherapy and immune cells extravasation into the tumor. This phase I clinical trial was aimed to find the maximum tolerated dose/recommended phase II dose (RP2D) and dose-limiting toxicity (DLT) of the intravenous delivery of the replication-competent VCN-01 adenovirus in patients with advanced cancer.Part I: patients with advanced refractory solid tumors received one single dose of VCN-01. Parts II and III: patients with pancreatic adenocarcinoma received VCN-01 (only in cycle 1) and nab-paclitaxel plus gemcitabine (VCN-concurrent on day 1 in Part II, and 7 days before chemotherapy in Part III). Patients were required to have anti-Ad5 neutralizing antibody (NAbs) titers lower than 1/350 dilution. Pharmacokinetic and pharmacodynamic analyses were performed.26% of the patients initially screened were excluded based on high NAbs levels. Sixteen and 12 patients were enrolled in Part I and II, respectively: RP2D were 1×1013 viral particles (vp)/patient (Part I), and 3.3×1012 vp/patient (Part II). Fourteen patients were included in Part III: there were no DLTs and the RP2D was 1×1013 vp/patient. Observed DLTs were grade 4 aspartate aminotransferase increase in one patient (Part I, 1×1013 vp), grade 4 febrile neutropenia in one patient and grade 5 thrombocytopenia plus enterocolitis in another patient (Part II, 1×1013 vp). In patients with pancreatic adenocarcinoma overall response rate were 50% (Part II) and 50% (Part III). VCN-01 viral genomes were detected in tumor tissue in five out of six biopsies (day 8). A second viral plasmatic peak and increased hyaluronidase serum levels suggested replication after intravenous injection in all patients. Increased levels of immune biomarkers (interferon-γ, soluble lymphocyte activation gene-3, interleukin (IL)-6, IL-10) were found after VCN-01 administration.Treatment with VCN-01 is feasible and has an acceptable safety. Encouraging biological and clinical activity was observed when administered in combination with nab-paclitaxel plus gemcitabine to patients with pancreatic adenocarcinoma.NCT02045602.
TEMPORAL TRENDS OF NEONATAL BRAIN INJURY IN COMPLEX CONGENITAL HEART DISEASE: RESULTS FROM A 20 YEAR PROSPECTIVE COHORT STUDY
Authors: Shabnam Peyvandi, Duan Xu, A. James Barkovich, Dawn Gano, Vann Chau, Thiviya Selvanathan, J. William Gaynor, Michael Seed, Steven Miller, Patrick McQuillen
Journal: Journal of the American College of Cardiology (2022)
THE ROLE OF TRANSCATHETER AORTIC VALVE REPLACEMENT IN LOW-FLOW, LOW-GRADIENT AORTIC STENOSIS: INSIGHTS FROM THE EVOLUT LOW RISK TRIAL
Authors: Saif Anwaruddin, John K. Forrest, Hemal Gada, Mubashir A. Mumtaz, Jian Huang, Brijeshwar Singh Maini, Jae K. Oh, Saki Ito, Neal S. Kleiman, Michael J. Reardon
Journal: Journal of the American College of Cardiology (2022)
DE-ESCALATION FROM PRASUGREL OR TICAGRELOR TO CLOPIDOGREL IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS
Authors: Joseph Shehata, Basel Abdelazeem, Kirellos Said Abbas, Nahla Ahmed El-Shahat, Nischit Baral, Govinda Adhikari, Hafiz Khan, Mustafa Hassan
Journal: Journal of the American College of Cardiology (2022)
AN INTERESTING CASE OF CMV MYOPERICARDITIS IN AN IMMUNOCOMPETENT PATIENT
Authors: Zurain Niaz, Robert Kropp, Luke Schiller, Prashanth Singanallur, Venkata Missula, Kevin Schrader, Mohamad Sukkari, Daniel Holtz, Michael Gleason, Muhammad Adil Sheikh, Raj Patel, Manjari R. Regmi, Abhishek Kalidas Kulkarni
Journal: Journal of the American College of Cardiology (2022)
We need to think more about how we conduct research
Authors: Gerd Gigerenzer
Journal: Behavioral and Brain Sciences (2022)

Abstract Research practice is too often shaped by routines rather than reflection. The routine of sampling subjects, but not stimuli, is a case in point, leading to unwarranted generalizations. It likely originated out of administrative rather than scientific concerns. The routine of sampling subjects and testing their averages for significance is reinforced by delusions about its meaningfulness, including the replicability delusion.
Dynamic contrast enhanced MRI for the evaluation of lung perfusion in idiopathic pulmonary fibrosis
Authors: Luis A. Torres, Kristine E. Lee, Gregory P. Barton, Andrew D. Hahn, Nathan Sandbo, Mark L. Schiebler, Sean B. Fain
Journal: European Respiratory Journal (2022)

Background The objective of this work was to apply quantitative and semiquantitative dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) methods to evaluate lung perfusion in idiopathic pulmonary fibrosis (IPF). Methods In this prospective trial 41 subjects, including healthy control and IPF subjects, were studied using DCE-MRI at baseline. IPF subjects were then followed for 1 year; progressive IPF (IPF prog ) subjects were distinguished from stable IPF (IPF stable ) subjects based on a decline in percent predicted forced vital capacity (FVC % pred) or diffusing capacity of the lung for carbon monoxide ( D LCO % pred) measured during follow-up visits. 35 out of 41 subjects were retained for final baseline analysis (control: n=15; IPF stable : n=14; IPF prog : n=6). Seven measures and their coefficients of variation (CV) were derived using temporally resolved DCE-MRI. Two sets of global and regional comparisons were made: control versus IPF groups and control versus IPF stable versus IPF prog groups, using linear regression analysis. Each measure was compared with FVC % pred, D LCO % pred and the lung clearance index (LCI % pred) using a Spearman rank correlation. Results DCE-MRI identified regional perfusion differences between control and IPF subjects using first moment transit time (FMTT), contrast uptake slope and pulmonary blood flow (PBF) (p≤0.05), while global averages did not. FMTT was shorter for IPF prog compared with both IPF stable (p=0.004) and control groups (p=0.023). Correlations were observed between PBF CV and D LCO % pred (r s = −0.48, p=0.022) and LCI % pred (r s = +0.47, p=0.015). Significant group differences were detected in age (p&lt;0.001), D LCO % pred (p&lt;0.001), FVC % pred (p=0.001) and LCI % pred (p=0.007). Conclusions Global analysis obscures regional changes in pulmonary haemodynamics in IPF using DCE-MRI in IPF. Decreased FMTT may be a candidate marker for IPF progression.
Supporting families with tuberculosis during COVID-19 in Khayelithsa, South Africa
Authors: Ivy Apolisi, Nandipha Mema, Nolitha Tyeku, Busisiwe Beko, Boniwe Memani, Johnny Daniels, Lwando Cengani, Siphokazi Fatshe, Nompumelelo Gumede, Mlungisi Makhalima, Shaheed Mathee, Gillian Matthews, Noluvo Ngambu, Amanda Ryan, Vera Scott, Janet Giddy, Jennifer Furin, Anja Reuter
Journal: The Lancet Respiratory Medicine (2022)
Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes
Authors: Sung Hwan Lee, Sun Young Yim, Yun Seong Jeong, Qi‐Xiang Li, Sang‐Hee Kang, Bo Hwa Sohn, Shwetha V. Kumar, Ji‐Hyun Shin, You Rhee Choi, Jae‐Jun Shim, Hayeon Kim, Ji Hoon Kim, Shin Kim, Sheng Guo, Randy L. Johnson, Ahmed Kaseb, Koo Jeong Kang, Yun Shin Chun, Hee Jin Jang, Byoung Gill Lee, Hyun Goo Woo, Min Jin Ha, Rehan Akbani, Lewis R. Roberts, David A. Wheeler, Ju‐Seog Lee
Journal: Hepatology (2022)

Although many studies revealed transcriptomic subtypes of HCC, concordance of the subtypes are not fully examined. We aim to examine a consensus of transcriptomic subtypes and correlate them with clinical outcomes.
Adoptive therapy with <scp>cytomegalovirus</scp>‐specific T cells for <scp>cytomegalovirus</scp> infection after haploidentical stem cell transplantation and factors affecting efficacy
Authors: Xu‐Ying Pei, Xiang‐Yu Zhao, Xue‐Fei Liu, Xiao‐Dong Mo, Meng Lv, Lan‐Ping Xu, Yu Wang, Ying‐Jun Chang, Xiao‐Hui Zhang, Kai‐Yan Liu, Xiao‐Jun Huang
Journal: American Journal of Hematology (2022)

Abstract Adoptive therapy with cytomegalovirus (CMV)‐specific cytotoxic T lymphocytes (CMV‐CTLs) has emerged as an effective method for CMV infection. However, the efficacy reportedly ranges from 50% to 90%, and factors affecting anti‐CMV efficacy have not been established. We investigated the safety and efficacy of adoptive therapy with CMV‐CTLs for CMV infection in 190 patients after haploidentical stem cell transplantation (haplo‐SCT), and importantly, we analyzed the main factors affecting antiviral efficacy. The CMV peak titer decreased from 19 (range, 1.0–503.0) × 10 3 copies/mL to 3.9 (range, 0–112) × 10 3 copies/mL after CMV‐CTL infusion. The cumulative complete response (CR) rates in the first, fourth, and sixth weeks after the first CMV‐CTL infusion were 37.9% (95% CI 35.0–40.8), 76.8% (95% CI 70.7–82.9), and 89.5% (95% CI 85.2–93.8), respectively. In multivariate analysis, persistent CMV infection prior to CMV‐CTL infusion (hazard ratio [HR] 2.29, 95% CI 1.29–4.06, p = .005) and basiliximab treatment within 2 weeks of CMV‐CTL infusion (HR 1.87, 95% CI 1.06–3.81, p = .031) were independent predictors of poor antiviral efficacy of CMV‐CTL therapy. Our data showed that adoptive therapy with CMV‐CTLs is a safe and effective treatment for CMV infection after haplo‐SCT. Persistent CMV infection and basiliximab treatment are correlated with poor anti‐CMV efficacy of CMV‐CTL therapy.
Tankyrase represses autoinflammation through the attenuation of TLR2 signaling
Authors: Yoshinori Matsumoto, Ioannis D. Dimitriou, Jose La Rose, Melissa Lim, Susan Camilleri, Napoleon Law, Hibret A. Adissu, Jiefei Tong, Michael F. Moran, Andrzej Chruscinski, Fang He, Yosuke Asano, Takayuki Katsuyama, Ken-ei Sada, Jun Wada, Robert Rottapel
Journal: Journal of Clinical Investigation (2022)

Dysregulation of Toll-like receptor (TLR) signaling contributes to the pathogenesis of autoimmune diseases. Here, we provide genetic evidence that tankyrase, a member of the poly(ADP-ribose) polymerase (PARP) family, negatively regulates TLR2 signaling. We show that mice lacking tankyrase in myeloid cells developed severe systemic inflammation with high serum inflammatory cytokine levels. We provide mechanistic evidence that tankyrase deficiency resulted in tyrosine phosphorylation and activation of TLR2 and show that phosphorylation of tyrosine 647 within the TIR domain by SRC and SYK kinases was critical for TLR2 stabilization and signaling. Last, we show that the elevated cytokine production and inflammation observed in mice lacking tankyrase in myeloid cells were dependent on the adaptor protein 3BP2, which is required for SRC and SYK activation. These data demonstrate that tankyrase provides a checkpoint on the TLR-mediated innate immune response.
Off-Label Use of Tenecteplase for the Treatment of Acute Ischemic Stroke
Authors: Aristeidis H. Katsanos, Klearchos Psychogios, Guillaume Turc, Simona Sacco, Diana Aguiar de Sousa, Gian Marco De Marchis, Lina Palaiodimou, Dimitrios K. Filippou, Niaz Ahmed, Amrou Sarraj, Bijoy K. Menon, Georgios Tsivgoulis
Journal: JAMA Network Open (2022)

<h3>Importance</h3> Tenecteplase is being evaluated as an alternative thrombolytic agent for the treatment of acute ischemic stroke (AIS) within ongoing randomized clinical trials (RCTs). In addition, nonrandomized clinical experiences with off-label use of tenecteplase vs alteplase for AIS treatment are being published. <h3>Objective</h3> To evaluate the available evidence on the safety and efficacy of intravenous tenecteplase compared with intravenous alteplase provided by nonrandomized studies. <h3>Data Sources</h3> Eligible studies were identified by searching MEDLINE and Scopus databases. No language or other restrictions were imposed. The literature search was conducted on October 12, 2021. This meta-analysis used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was written according to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) proposal. <h3>Study Selection</h3> Nonrandomized studies (prospective or retrospective) comparing intravenous tenecteplase (at any dose) with intravenous alteplase in patients with AIS were included in the analysis. <h3>Data Extraction and Synthesis</h3> The crude odds ratios (ORs) and 95% CIs were calculated for the association of tenecteplase vs alteplase with the outcomes of interest and adjusted ORs were extracted if provided. Estimates using random-effects models were pooled. <h3>Main Outcomes and Measures</h3> The primary outcome was the probability of good functional outcome (modified Rankin scale [mRS] score, 0-2) at 90 days. <h3>Results</h3> Six studies were identified including a total of 1820 patients (618 [34%] treated with tenecteplase). Patients receiving tenecteplase had higher odds of 3-month good functional outcome (crude odds ratio [OR], 1.22; 95% CI, 0.90-1.66; adjusted OR, 1.60, 95% CI, 1.08-2.37), successful recanalization (crude OR, 2.82; 95% CI, 1.12-7.10; adjusted OR, 2.38; 95% CI, 1.18-4.81), and early neurological improvement (crude OR, 4.88; 95% CI, 2.03-11.71; adjusted OR, 7.60; 95% CI, 1.97-29.41). No significant differences were detected in 3-month excellent functional outcome proportions (mRS score 0-1; crude OR, 1.53; 95% CI, 0.81-2.91; adjusted OR, 2.51; 95% CI, 0.66- 9.49), symptomatic intracranial hemorrhage (crude OR, 0.97; 95% CI, 0.44-2.16; adjusted OR, 1.16; 95% CI, 0.13-10.50), or parenchymal hematoma (crude OR, 1.20; 95% CI, 0.24-5.95). <h3>Conclusions and Relevance</h3> Evidence from nonrandomized studies suggests tenecteplase is as safe as alteplase and potentially associated with improved functional outcomes compared with alteplase. Based on these findings, enrollment in the ongoing RCTs appears to be appropriate.
Thrombolysis or Surgery in Patients With Obstructive Mechanical Valve Thrombosis
Authors: Mehmet Özkan, Sabahattin Gündüz, Ahmet Güner, Macit Kalçık, Mustafa Ozan Gürsoy, Begüm Uygur, Nurşen Keleş, Hasan Kaya, Alev Kılıçgedik, Emrah Bayam, Semih Kalkan, Mehmet Ali Astarcıoğlu, Süleyman Karakoyun, Mahmut Yesin, Duygu İnan, Ali Fedakar, Sabit Sarıkaya, Mehmet Aksüt, Burak Onan, Cevdet Uğur Koçoğulları
Journal: Journal of the American College of Cardiology (2022)
Opportunities and challenges for the development of “core outcome sets” in neuro-oncology
Authors: Christopher P Millward, Terri S Armstrong, Heather Barrington, Andrew R Brodbelt, Helen Bulbeck, Anthony Byrne, Linda Dirven, Carrol Gamble, Paul L Grundy, Abdurrahman I Islim, Mohsen Javadpour, Sumirat M Keshwara, Sandhya T Krishna, Conor L Mallucci, Anthony G Marson, Michael W McDermott, Torstein R Meling, Kathy Oliver, Barry Pizer, Puneet Plaha, Matthias Preusser, Thomas Santarius, Nisaharan Srikandarajah, Martin J B Taphoorn, Colin Watts, Michael Weller, Paula R Williamson, Gelareh Zadeh, Amir H Zamanipoor Najafabadi, Michael D Jenkinson
Journal: Neuro-Oncology (2022)

Core Outcome Sets (COS) define minimum outcomes to be measured and reported in clinical effectiveness trials for a particular health condition/health area. Despite recognition as critical to clinical research design for other health areas, none have been developed for neuro-oncology. COS development projects should carefully consider: scope (how the COS should be used), stakeholders involved in development (including patients as both research partners and participants), and consensus methodologies used (typically a Delphi survey and consensus meeting), as well as dissemination plans. Developing COS for neuro-oncology is potentially challenging due to extensive tumor subclassification (including molecular stratification), different symptoms related to anatomical tumor location, and variation in treatment options. Development of a COS specific to tumor subtype, in a specific location, for a particular intervention may be too narrow and would be unlikely to be used. Equally, a COS that is applicable across a wider area of neuro-oncology may be too broad and therefore lack specificity. This review describes why and how a COS may be developed, and discusses challenges for their development, specific to neuro-oncology. The COS under development are briefly described, including: adult glioma, incidental/untreated meningioma, meningioma requiring intervention, and adverse events from surgical intervention for pediatric brain tumors.
Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis
Authors: Evan B Cunningham, Alice Wheeler, Behzad Hajarizadeh, Clare E French, Rachel Roche, Alison D Marshall, Guillaume Fontaine, Anna Conway, Braulio M Valencia, Sahar Bajis, Justin Presseau, John W Ward, Louisa Degenhardt, Gregory J Dore, Matthew Hickman, Peter Vickerman, Jason Grebely
Journal: The Lancet. Gastroenterology & hepatology (2022)
AORTIC VALVE CALCIUM SCORE IN COMPARISON TO DOBUTAMINE STRESS ECHOCARDIOGRAPHY IN THE ASSESSMENT OF SEVERE LOW FLOW LOW GRADIENT AORTIC STENOSIS
Authors: Ola Abdelkarim, Abhiraj Sinha, Ramez Barsoom, Nadeen Nader Faza, Su Min Chang
Journal: Journal of the American College of Cardiology (2022)
THE ASSOCIATION OF E/E’ RATIO WITH POOR SURVIVAL AMONG HEALTHY SUBJECTS IS MODIFIED BY SEX AND AGE
Authors: Yishay Wasserstrum, Rami Gilead, Rafael Kuperstein, Sagit Ben-Zekry, Ori Vaturi, Efrat Mazor-Dray, Ilan Hay, Amit Segev, Micha S. Feinberg, Elad Maor
Journal: Journal of the American College of Cardiology (2022)
ATRIAL FIBRILLATION IS ASSOCIATED WITH BLUNTED AND UNFAVORABLE TRICUSPID ANNULUS DYNAMICS
Authors: Jwan Naser, Cristina Pislaru, Aslannif Roslan, Andrea Olivia Ciobanu, Hayan Jouni, Vuyisile Tlhopane Nkomo, Garvan C. Kane, Sorin Pislaru
Journal: Journal of the American College of Cardiology (2022)
BETABLOCKERS PREVENT ACUTE MYOCARDIAL INFARCTION BY DISTAL VASOCONSTRICTION AND SLOWER SPEED IN PROXIMAL SEGMENT: AN ANGIOGRAPHIC AND MACHINE LEARNING ANALYSIS
Authors: Thach N. Nguyen, Nhu M. Lam, Tai Thien Tan Tri Truyen, Loc Vu, Ernest Talarico, Thoa Le, Thien H. Pham, Hung N. Pham, Dung Thuong Ho, Thinh Cao, Gianluca Rigatelli
Journal: Journal of the American College of Cardiology (2022)
Intra-articular Platelet-Rich Plasma vs Placebo Injection and Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis
Authors: Jeremy Magalon, Alain Frey, Jean-Francois Kaux
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A SINGLE-DOSE INTRAVENOUS MELATONIN ADMINISTRATION AFTER ISCHEMIA EFFECTIVELY ATTENUATES CARDIAC ISCHEMIA-REPERFUSION INJURY IN PREDIABETIC RATS
Authors: Kodchanan Singhanat, Nattayaporn Apaijai, Natticha Sumneang, Chayodom Maneechote, Busarin Arunsak, Titikorn Chunchai, Siriporn Chattipakorn, Nipon Chattipakorn
Journal: Journal of the American College of Cardiology (2022)
<scp>miR</scp> ‐378a regulates keratinocyte responsiveness to <scp>interleukin‐17A</scp> in psoriasis*
Authors: Ping Xia, Lorenzo Pasquali, Chenying Gao, Ankit Srivastava, Nupur Khera, Jan Cedric Freisenhausen, Longlong Luo, Einar Rosén, Anke van Lierop, Bernhard Homey, Andor Pivarcsi, Enikö Sonkoly
Journal: British Journal of Dermatology (2022)

Psoriasis is an immune-mediated inflammatory skin disease, in which an interplay between infiltrating immune cells and keratinocytes sustains chronic skin inflammation. Interleukin (IL)-17A is a key inflammatory cytokine in psoriasis and its main cellular targets are keratinocytes.To explore the role of miR-378a in psoriasis.Keratinocytes obtained from psoriatic skin and healthy epidermis were separated by magnetic sorting, and the expression of miR-378a was analysed by quantitative polymerase chain reaction. The regulation and function of miR-378a was studied using primary human keratinocytes. The expression of miR-378a was modulated by synthetic mimics, and nuclear factor kappa B (NF-κB) activity and transcriptomic changes were studied. Synthetic miR-378a was delivered to mouse skin in conjunction with induction of psoriasiform skin inflammation by imiquimod.We show that miR-378a is induced by IL-17A in keratinocytes through NF-κB, C/EBP-β and IκBζ and that it is overexpressed in psoriatic epidermis. In cultured keratinocytes, ectopic expression of miR-378a resulted in the nuclear translocation of p65 and enhanced NF-κB-driven promoter activity even in the absence of inflammatory stimuli. Moreover, miR-378a potentiated the effect of IL-17A on NF-κB nuclear translocation and downstream activation of the NF-κB pathway. Finally, injection of miR-378a into mouse skin augmented psoriasis-like skin inflammation with increased epidermal proliferation and induction of inflammatory mediators. Mechanistically, miR-378a acts as a suppressor of NFKBIA/IκBζ, an important negative regulator of the NF-κB pathway in keratinocytes.Collectively, our findings identify miR-378a as an amplifier of IL-17A-induced NF-κB signalling in keratinocytes and suggest that increased miR-378a levels contribute to the amplification of IL-17A-driven skin inflammation in psoriasis.
WORSE VASCULAR RISK FACTOR CONTROL IN PATIENTS WITH STROKE COMPARED TO PATIENTS WITH MYOCARDIAL INFARCTION
Authors: Audrey Leasure, Julian Acosta, Anna Schwartz, Rachel Forman, Richa Sharma, Adam de Havenon, Guido J. Falcone, Silvio E. Inzucchi, Walter Kernan, Kevin N. Sheth
Journal: Journal of the American College of Cardiology (2022)
QIM22-204: A Retrospective Analysis and Quality Improvement Project to Increase Breast Cancer Screening in Northwestern Medicine Hospital, Internal Medicine Residency Clinic
Authors: Nayha Tahir, Grace Ying, Sonika Prasad, Aatma Ram
Journal: Journal of the National Comprehensive Cancer Network (2022)

"QIM22-204: A Retrospective Analysis and Quality Improvement Project to Increase Breast Cancer Screening in Northwestern Medicine Hospital, Internal Medicine Residency Clinic" published on 31 Mar 2022 by National Comprehensive Cancer Network.
WHEN THE ODDS ARE NOT IN YOUR FAVOR- PERCUTANEOUS MANAGEMENT OF CORONARY PERFORATION AND TAMPONADE FOLLOWING ROTATIONAL ATHERECTOMY IN A PATIENT WITH CIRRHOSIS
Authors: Hussam Al Hennawi, Lein Mathbout, Mohammad Mathbout, Anbukarasi Maran, Valerian L. Fernandes
Journal: Journal of the American College of Cardiology (2022)